Hattie Hayes is the editor of Ophthalmology Times Europe.
Advanced therapies in neovascular AMD and DMO: Experts weigh in
A clinician panel illuminates current treatment paradigms and best practices for reducing treatment burden
Heidelberg Engineering announces two-day International SPECTRALIS Symposium
The event will include presentations on artificial intelligence, ocular imaging and surgical topics
US FDA approves revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2
The encapsulated cell therapy from Neurotech Pharmaceuticals is the first FDA-approved treatment for MacTel
EMA provides positive ATMP opinion for gene therapy products OCU410 and OCU410ST
The modifier gene therapies from Ocugen target geographic atrophy and Stargardt disease
Preview: The ESCRS Winter Meeting comes to Athens
This year, the European Society of Cataract and Refractive Surgeons has partnered with the Hellenic Society of Intraocular Implant and Refractive Surgery
Zeiss Visumax 800 with SMILE pro software receives NMPA approval in China
The Visumax 800 boasts a faster laser pulse repetition rate for shorter procedures
Study demonstrates visual acuity improvements following gene therapy for AIPL1-associated inherited retinal dystrophies
Researchers indicated that paediatric patients with Leber congenital amaurosis experienced improvements in vision
UK MHRA issues approval for Formycon aflibercept biosimilar FYB203 (Ahzantive)
The biosimilar to aflibercept (Eylea) has already received approval in the EU and US
Why education must extend beyond patients to make a difference in diabetic eye disease
Francesco Bandello, MD, FEBO, discusses the Diabetic Eye Conditions Coalition and a five-point call to action
EMA validates indication extension application of pegcetacoplan for treatment of kidney disease
According to Apellis and Sobi, pegcetacoplan (Aspaveli) first received marketing authorisation for treatment of paroxysmal nocturnal hemoglobinuria
Heart Eye announces AI-driven retinal imaging system to detect biomarkers of cardiovascular health risks
The UK-based company will debut the tool, called Dr.Noon CVD, at two conferences in March
Angiogenesis 2025: The global forecast for AI-driven home OCT
Professor Anat Loewenstein, MD, speaks about her presentation from the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting
GenSight Biologics shares efficacy and safety findings from REFLECT Phase III gene therapy trial
The company shared 5-year results for lenadogene nolparvovec (Lumevoq), administered unilaterally and bilaterally to patients with Leber Hereditary Optic Neuropathy
An accessible, free resource on genetic eye disease is changing patient education
Mariya Moosajee, MBBS, BSc, PhD, FRCOphth, discusses how Gene Vision is improving patients' lives on a global scale
Study indicates age and gender are factors in ocular gene therapy outcomes
Researchers from the University of Bristol recorded increased instances of inflammation in particular demographic groups
Shifting the narrative around dry eye disease
A qualitative study method illuminates patients’ fears for the future
Crafting an international database for retinopathy of prematurity
Intercontinental collaboration is key to unlocking ROP in our lifetime
European Medicines Agency CHMP adopts positive opinions for two aflibercept biosimilars
Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration
SeaBeLife announces preclinical efficacy results for SBL03 topical ophthalmic gel
The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections
Deafblind UK and Birmingham City University announce education and research centre
The centre will facilitate research and access to resources for the 450,000 residents of the UK who are affected by sight and hearing loss
NeurEYE research team leads AI-supported dementia detection programme with Scottish optometrists
Predictive software will use retinal imaging to identify patient risk for Alzheimer and other neurodegenerative diseases
PulseSight Therapeutics submits Clinical Trial Authorisation for phase I trial of PST-611
The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy
Teva partners with Klinge Biopharma, Lotus Pharmaceutical for commercialisation of Formycon’s FYB203 (biosimilar aflibercept)
The commercialisation agreements for the biosimilar to aflibercept (Eylea) cover Israel, major parts of Europe and the Asia-Pacific Region
ViGeneron receives rare paediatric disease designation from US FDA for retinitis pigmentosa gene therapy candidate VG901
ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial
Regeneron acquires UK biotech company Oxular, broadening retina portfolio
In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular oedema
Wrapping up another year in eye care: 2024 in review
Trending topics and milestone stories from our year in ophthalmology
See the best of our print edition with the 2024 cover story roundup
Our top 10 print stories highlight the core content concepts we explored this year
European Medicines Agency will assess semaglutide for link to NAION
The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition
A neurologist shares his warning about recurrent optic neuritis attacks and NMOSD
Ocular clues to a neurological conditions help clinicians understand neuromyelitis optica spectrum disorder (NMOSD)
EMA CHMP issues positive opinion for aflibercept biosimilar, two other candidates from Celltrion
The European Commission will assess the marketing authorisation for Eydenzelt (reference product Eylea)